Merck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow MRK
Merck & Co., Inc. (MRK) EV/FCF
As of 9 October 2026, Merck & Co., Inc. (MRK) trades at a EV/FCF of 25.1×. Over the past ten years it has ranged from 12.3× (May 2025) to 532× (December 2020); the current reading is higher than 50% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 23.9× | 58.70% |
| FY2024 | 15.1× | (56.11%) |
| FY2023 | 34.3× | 70.02% |
| FY2022 | 20.2× | (19.10%) |
| FY2021 | 25.0× | (62.95%) |
| FY2020 | 67.4× | 58.19% |
| FY2019 | 42.6× | 72.43% |
| FY2018 | 24.7× | (29.26%) |
| FY2017 | 34.9× | 81.34% |
| FY2016 | 19.3× | 42.26% |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 22.5× | (6.15%) |
| Mar 2026 | 24.0× | 0.24% |
| Dec 2025 | 23.9× | 34.98% |
| Sep 2025 | 17.7× | 16.41% |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| GILD Gilead Sciences, Inc. compare | 16.3× |
| NVS Novartis AG compare | 20.6× |
| PFE Pfizer Inc. compare | 20.9× |
| NVO Novo Nordisk A/S compare | 24.4× |
| MRK Merck & Co., Inc. | 25.1× |
| AMGN Amgen Inc. compare | 27.4× |
| JNJ Johnson & Johnson compare | 28.4× |
| ABBV AbbVie Inc. compare | 30.4× |
| AZN AstraZeneca PLC compare | 43.3× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on MRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement